In this deep dive, BioSpace looks at recent breakthroughs and three decades of progress in treating Huntington's disease.
Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback